Astellas Pharma Inc. · TSE:4503
Astellas Pharma — Q2 2017 Earnings Presentation
5 slides from Astellas Pharma's earnings presentation, October 2017
Slide 1: R&D Pipeline (As of Oct 2017) - Oncology (1/2)
R&D Pipeline (As of Oct 2017) Underlined items indicate changes from the previous announcement on July 28, 2017. Oncology (1/2) *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Classification Target Disease Phase / Area Licensor* Remarks Ge
Slide 2: Oncology (2/2)
Oncology (2/2) *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Classification Target Disease Phase / Area Licensor* Remarks Generic Name Form AGS62P1 Acute myeloid leukemia P-I Injection In-house (ADC technology, EuCODE license from Ambrx)
Slide 3: Urology and Nephrology
Urology and Nephrology *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Classification Target Disease Phase / Area Licensor* Remarks Generic Name Form YM905 Muscarine M3 receptor antagonist Neurogenic detrusor overactivity in pediatric pati
Slide 4: Immunology and Neuroscience
Immunology and Neuroscience *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Classification Target Disease Phase / Area Licensor* Remarks Generic Name Form FK506 Immunosuppressant Prevention of rejection after organ transplantation Filed (J
Slide 5: Others
Others *Compounds with "In-house" in this column include ones discovered by collaborative research. Code No. Dosage Classification Target Disease Phase / Area Licensor* Remarks Generic Name Form AMG 785 Anti-Sclerostin Osteoporosis for those at high risk of fracture Filed (Dec. 2016) / Japan Injecti
Astellas Pharma — Q2 2017 Earnings Presentation on 6ix